Macular Edema - Pipeline Review, H2 2017

  • ID: 4433864
  • Report
  • 42 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Coherus BioSciences Inc
  • Lupin Ltd
  • Mabion SA
  • OMEICOS Therapeutics GmbH
  • Promedior Inc
  • Xbrane Biopharma AB
  • MORE
Macular Edema - Pipeline Review, H2 2017

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Macular Edema - Pipeline Review, H2 2017, provides an overview of the Macular Edema (Ophthalmology) pipeline landscape.

Macular edema is swelling or fluid retention in a specialized part of the retina called the macula. Symptoms of macular edema include blurred or wavy central vision and/or colors appear changed. There are many causes of macular edema. It is frequently associated with diabetes, where damaged blood vessels in the retina begin to leak fluids, including small amounts of blood, into the retina. Other causes include retinal vein occlusion, side effects of certain medications and certain genetic disorders, such as retinoschisis or retinitis pigmentosa.

Report Highlights

The latest Pharmaceutical and Healthcare latest pipeline guide Macular Edema - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Macular Edema (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Macular Edema (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Macular Edema and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 1, 7 and 2 respectively.

Macular Edema (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Macular Edema (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Macular Edema (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Macular Edema (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Macular Edema (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Macular Edema (Ophthalmology)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Macular Edema (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Macular Edema (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Coherus BioSciences Inc
  • Lupin Ltd
  • Mabion SA
  • OMEICOS Therapeutics GmbH
  • Promedior Inc
  • Xbrane Biopharma AB
  • MORE
Introduction

Macular Edema - Overview

Macular Edema - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Macular Edema - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Macular Edema - Companies Involved in Therapeutics Development

ActiveSite Pharmaceuticals Inc

Coherus BioSciences Inc

Lupin Ltd

Mabion SA

OMEICOS Therapeutics GmbH

Promedior Inc

Taiwan Liposome Company Ltd

Xbrane Biopharma AB

Macular Edema - Drug Profiles

ACX-107 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aflibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASPPDC-020 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dexamethasone sodium phosphate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HO-10 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMT-28 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRM-167 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ranibizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ranibizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ranibizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Macular Edema - Dormant Projects

Macular Edema - Discontinued Products

Macular Edema - Product Development Milestones

Featured News & Press Releases

Jul 25, 2017: TLC to Receive Government Grant for Development of Ophthalmology Product Candidate TLC399

Oct 01, 2015: Patent Granted by SIPO for TLCs Ophthalmic Drug Delivery System

Jan 06, 2015: Government Subsidy of NT$17.6M granted for TLC’s Ophthalmology Drug Phase I/II trial

Dec 23, 2013: TLC receives FDA IND approval for Sustained Release Macular Disease Drug

Sep 24, 2013: Patent Approval granted by USPTO for TLC’s BioSeizer Platform

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Macular Edema, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Macular Edema - Pipeline by ActiveSite Pharmaceuticals Inc, H2 2017

Macular Edema - Pipeline by Coherus BioSciences Inc, H2 2017

Macular Edema - Pipeline by Lupin Ltd, H2 2017

Macular Edema - Pipeline by Mabion SA, H2 2017

Macular Edema - Pipeline by OMEICOS Therapeutics GmbH, H2 2017

Macular Edema - Pipeline by Promedior Inc, H2 2017

Macular Edema - Pipeline by Taiwan Liposome Company Ltd, H2 2017

Macular Edema - Pipeline by Xbrane Biopharma AB, H2 2017

Macular Edema - Dormant Projects, H2 2017

Macular Edema - Discontinued Products, H2 2017

List of Figures

Number of Products under Development for Macular Edema, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Targets, H2 2017

Number of Products by Stage and Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • ActiveSite Pharmaceuticals Inc
  • Coherus BioSciences Inc
  • Lupin Ltd
  • Mabion SA
  • OMEICOS Therapeutics GmbH
  • Promedior Inc
  • Taiwan Liposome Company Ltd
  • Xbrane Biopharma AB
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll